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ABSTRACT 
The objective of the present study was to develop and optimize a buoyant tablet of 
Nateglinide to prolong the gastric residence time leading to reduce dose frequency 
which is an effective drug in the treatment of type II diabetes. The tablets were 
prepared by wet granulation technique using chitosan as a natural polymer in different 
ratios with sodium bicarbonate as gas generating agent. The compatibility of 
Nateglinide and all excipients were confirmed by FTIR spectroscopy. Pre-compression 
properties of granules are found within the prescribed limits and indicated good flow 
property. The tablets were evaluated for physical characteristics had shown that all of 
them comply with specifications of official pharmacopoeias. An optimized tablet 
formulation (F7) had less buoyancy lag time of 37 sec, total floating time of >12 hrs and 
higher the drug content of 100.16% and release of Nateglinide was 97.27 % after the 
end of 12 hours. From the kinetic modeling results, the drug release was Fickian 
diffusion controlled and followed zero order kinetics.  
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INTRODUCTION 
Most of the oral dosage forms posses several 
physiological limitations such as variable 
gastrointestinal transit time because of variable 
gastric emptying leading to no uniform absorption 
profiles, incomplete drug release and shorter 
residence time of the dosage form in the stomach[1]. 
This leads to incomplete absorption of drugs having 
absorption window especially in the upper art of the 
small intestine, as once the drug passes down the 
absorption site, the remaining quantity goes 
unabsorbed[2]. However, the short gastric retention 
time and unpredictable rapid gastric emptying rate 
can result in incomplete drug release from the dosage 
form in the absorption zone leading to decrease 
therapeutic efficacy of administered dose[3]. To 
increase the gastric residence time of drug a buoyant 
dosage form can be developed. Nateglinide is an anti-
diabetic agent belongs to meglitinides (glinides) class 
for the management of non-insulin dependent type-2 
diabetes mellitus[4]. Nateglinide is majorly absorbed 
from stomach but poorly soluble in aqueous fluids 
with shorter biological half life of 2 hours and need of 
frequent doses per day[5]. Therefore, controlled 
buoyant drug delivery systems are needed to 
enhance effectiveness of such drugs and to reduce 
dose of frequency.  In this study an attempt was made 
to develop buoyant matrix tablet of Nateglinide with 
naturally occurring chitosan polymer. 
MATERIALS AND METHODS 
Materials 
Nateglinide was obtained as a gift sample 
from Actiza Pharmaceutical Pvt. Ltd, Surat, India. 
Chitosan obtained as a gift sample from Medrich Pvt. 
Ltd. Bangalore. Microcrystalline cellulose, PVP, and 
Citric acid were procured from Reachem laboratory 
chemicals Pvt. Ltd. Chennai, India. Magnesium 
stearate and talc were procured from S.D. Fine 
chemicals Pvt. Ltd. Mumbai, India. All chemicals and 
solvents used were of analytical grades. 
METHODS 
Compatibility 
To study the various excipients of 
formulation with Nateglinide compatibility, a solid 
admixture were prepared by mixing the drug with all 
excipients of formulation at the ratio of 1:1 and 
stored in air tight container at 45±2ºC / 75±5% RH 
using stability chamber (Labtop, Skylab instrument 
and engineering Pvt. Ltd. Thane. India). After a period 
Int. J. Ayur. Pharma Research, 2019;7(10):27-34 
     IJAPR | October 2019 | Vol 7 | Issue 10  28 
of 3 months the solid admixture was characterized 
using FTIR spectroscopy. 
Preparation of Standard curve of Nateglinide 
50mg of Nateglinide were dissolved in 
methanol to get stock solution of 1000µg/ml. The 
above solution was subsequently diluted to get a 
series of dilutions containing 8-22µg/ml of 
Nateglinide solutions. The absorbance of the 
prepared dilutions was measured at 465nm by using 
UV-Spectrophotometer (Shimadzu UV-1800) using 
methanol as blank. The standard plotted against 
Concentration verses absorbance[6]. 
Preparation of Buoyant tablet 
Buoyant tablet of Nateglinide was prepared 
by conventional wet granulation technique. Each 
buoyant tablet containing 60mg of Nateglinide was 
prepared with varying ratio of chitosan as polymer 
and microcrystalline cellulose (MCC) as diluent, 
keeping all other excipients as constant in weight as 
shown in table no.1. A blend of Nateglinide and the 
required quantity of chitosan, MCC, sodium 
bicarbonate, citric acid and PVP K30 were mixed with 
solvent blend of methanol and water (1:1) to get a 
wet damp mass. The wet damp mass was passed 
through sieve no. 12 to get wet granules and granules 
dried at 60ºC for 1 hour. The dried granules was 
mixed with talc and Magnesium stearate, were 
compressed into tablet of hardness 4-5kg/sq.cm on a 
12 station Cadmic rotary tablet punch machine. 
Table 1: Formulations containing various quantities of excipients 
Ingredients F1 F2 F3 F4 F5 F6 F7 F8 F9 
Nateglinide 60 60 60 60 60 60 60 60 60 
Chitosan 05 10 15 20 25 30 35 40 45 
MCC 50 45 40 35 30 25 20 15 10 
PVP 10 10 10 10 10 10 10 10 10 
Sodium bicarbonate 20 20 20 20 20 20 20 20 20 
Magnesium stearate 02 02 02 02 02 02 02 02 02 
Talc 03 03 03 03 03 03 03 03 03 
*All quantities are in milligram (mg) 
Characterization 
Thickness, Hardness, Weight variation, and 
Friability determination 
Thickness was determined using Vernier 
calipers, hardness was measured by using a Pfizer 
hardness tester, weight variation was calculated as 
per the standards and friability was varied out Roche 
friabilator (M/s Techno scientific and equipments)[7]. 
Assay of Nateglinide 
10 tablets were selected randomly and 
powdered, powder were equivalent to 1 tablet was 
taken and allowed to dissolve on 100ml of methanol 
by placing in shaker for an hour. The solution was 
filtered and analyzed at 465nm using UV 
spectrophotometer after suitable dilutions.[8] 
Determination of Swelling Index (S.I)  
The swelling behavior of tablet was measured 
by considering its weight gain, after placing in 100ml 
of 0.1N HCL in beaker. After time intervals of 1,2,4,6 
and 8 hours each tablet was taken out from beaker, 
blotted with tissue paper to remove excess water and 
weighed on analytical balance. The experiment was 
carried in triplicate for each time point. The swelling 
index was calculated using following formula.[9] 
𝑺. 𝑰
=
𝑾𝒆𝒕 𝒘𝒆𝒊𝒈𝒉𝒕 𝒐𝒇 𝒕𝒂𝒃𝒍𝒆𝒕 − 𝑫𝒓𝒚 𝒘𝒆𝒊𝒈𝒉𝒕 𝒐𝒇 𝒕𝒂𝒃𝒍𝒆𝒕
𝑫𝒓𝒚 𝒘𝒆𝒊𝒈𝒉𝒕 𝒐𝒇 𝒕𝒂𝒃𝒍𝒆𝒕
𝒙 𝟏𝟎𝟎 
 
Buoyancy lag time and total floating time 
The time required to float a tablet from the 
bottom of the medium to the upper surface of the 
medium after placing in 100ml of 0.1N HCL in a 
beaker was determined as floating lag time and the 
duration of time to float a tablet constantly on the 
dissolution medium was noted as total floating time. 
The experiment was conducted in triplicate.[10] 
In-vitro drug release studies 
An 8 station dissolution rate test apparatus–II 
paddle type (Model– DS 8000, M/s Lab India) was 
used to study the release of Nateglinide from the 
tablet. The dissolution test was carried out by placing 
1 tablet containing 60mg of Nateglinide in 900ml of 
0.1N HCL at 37ºC ± 0.5ºC at a paddle speed of 50 rpm. 
After each 1 hour a sample of solution of 5ml was 
withdrawn from dissolution apparatus and same 
volume of fresh medium was replaced and assayed 
spectrophotometrically (Shimadzu UV-1800) at 
465nm after appropriate dilution. All the experiment 
was conducted in triplicate.[11] 
Kinetic modeling of drug release 
The drug release mechanism from a matrix 
system can be studied using various kinetic models, 
even though it is complicated but practically evident 
in the case of matrix system. The order of drug 
release from matrix was described by using zero 
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order and first order kinetics. The mechanism of drug 
release from the matrix was studied by using Higuchi 
equation and Koresmeyer-Pappa’s equation.[12] 
RESULTS AND DISCUSSION 
Compatibility study 
FTIR spectra of Nateglinide and excipients 
solid admixtures were recorded between 500 to 
3000 cm-1. The characteristic peaks of Nateglinide 
were observed at 1636 and 2932. No significant 
change observed in the characteristic peaks of 
Nateglinide in all the solid admixture of drug and 
excipients. The FTIR spectrum shows in figures1 and 
2. 
Pre-compression studies 
The prepared granules were subjected to 
various physical studies before compressing into 
tablets. Bulk density of the granules was found in the 
range of 0.25 g/cc to 0.39 g/cc and tapped density 
between 0.28 g/cc to 0.43 g/cc. the calculated Carr’s 
index was between 6.77 to 13.28 %. The flow 
property of the granules was assures by angle of 
repose, which was found between 23.56º to 27.39º 
for all formulation granules. The data is evidence of 
good flow behavior and compressibility. The results 
are shown in table no.2. 
Table 2: Pre-Compression Parameter results 
Formulation Bulk density 
g/cm3 
Tapped density g/cm3 Compressibility index  
 % 
Angle of  
 repose (º) 
F1 0.39 0.43 9.30 23.56 
F2 0.38 0.405 6.862 26.25 
F3 0.33 0.362 8.88 25.93 
F4 0.256 0.286 11.27 26.07 
F5 0.248 0.2861 13.28 27.39 
F6 0.391 0.424 7.78 26.82 
F7 0.309 0.334 7.48 27.07 
F8 0.352 0.382 8.45 25.93 
F9 0.33 0.354 6.77 24.96 
Physical properties of compressed tablets 
Weight variation for all the formulation was found to be in the range of 150mg ± 0.42mg to 150mg ± 
0.31mg. Hardness of the tablet was in the range of 5.03 to 5.91kg/cm2. The percentage loss of weight during 
friability test was 0.21% to 0.62% which is found to be within standard limit and sufficient hardness to 
withstand mechanical resistance. Thickness of formulated tablets was of between the ranges of 4.35 to 4.88 
mm. The drug content varied between 94.29 to 103.02% in all tablets with low standard variation indicating 
content uniformity of the prepared batches. All the physical properties are within the pharmacopoeial 
specifications and the above parameters are shown in table no.3. 
Table 3: Physical properties of compressed tablets (n = 3) 
Formulation Thickness 
 (mm) 
Weight  
Variation(mg) 
Hardness 
(kg/cm2) 
Friability 
(%) 
Drug 
content (%) 
F1 4.48±0.04 120±0.400 5.15±0.187 0.21±0.04 94.29 
F2 4.45±0.03 120±0.350 5.15±0.237 0.40±0.07 101.06 
F3 4.39±0.1 120±0.317 5.01±0.172 0.34±0.04 96.69 
F4 4.43±0.02 120±0.314 5.03±0.186 0.30±0.02 98.15 
F5 4.53±0.08 120±0.420 5.14±0.135 0.16±0.06 103.02 
F6 4.55±0.06 120±0.320 5.15±0.187 0.43±0.05 99.31 
F7 4.40±0.03 120±0.330 5.11±0.116 0.62±0.1 100.16 
F8 4.35±0.04 120±0.325 5.91±0.231 0.51±0.08 97.25 
F9 4.38±0.05 120±0.423 5.03±0.186 0.38±0.04 98.30 
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Buoyancy studies 
All the formulations shows lag time of between 37 sec to 81 sec. Buoyancy lag and total floating time of 
all the formulations are expressed in table no.4. Among all formulations F7 has least buoyant lag time of 37 sec. 
in 0.1N HCL and remained buoyant for 12 hours. The proportionate quantity of sodium bicarbonate (16.66%) 
to the quantity of chitosan is ideal to be buoyant for long period with the release of appropriate amount of CO2 
when it comes in contact with dissolution fluid. Due to the production of CO2 from the tablet matrix decrease 
the density of the tablet below one making that tablet buoyant.  
Table 4: Buoyancy lag time. Total floating time of formulation (F1- F9) (n=3) 
Formulation Buoyancy lag time (sec) Total floating time (hrs) 
F1 55±02 >10 
F2 49±01 >12 
F3 70±03 >11 
F4 74±01 >12 
F5 39±03 >12 
F6 81±02 >11 
F7 37±01 >12 
F8 76±04 >11 
F9 61±02 >10 
Swelling Index 
From the graphical representation (figure no. 3, 4) and value from the table no.5 swelling behavior of all 
the formulations is due to the formation of hydrogel by chitosan. The swelling index increases as the 
concentration of high molecular weight polymer increases. The comparative swelling behavior of all the 
formulations with respect to time is shown in figure 5. 
Table 5: Swelling index studies (n=3) 
Time in (hr) F1 F2 F3 F4 F5 F6 F7 F8 F9 
0 0 0 0 0 0 0 0 0 0 
1 1.2±
0.1 
4.2±
0.18 
10.2±
0.56 
15.6±
0.35 
21.4±
1.02 
25.6±
0.97 
43.4±
0.85 
48.1±
1.32 
59.9±
2.01 
2 2.5±
0.21 
5.6±
0.15 
14.6±
0.81 
18.3±
0.24 
28.3±
0.98 
29.7±
1.01 
60.1±
0.98 
69.4±
2.01 
80.3±
2.58 
4 3.1±
0.12 
7.4±
0.18 
18.5±
0.91 
21.5±
0.36 
34.2±
1.2 
30.4±
1.6 
84.7±
1.01 
93.2±
1.92 
117.4
±1.69 
6 3.7±
0.2 
8.3±
0.84 
20.8±
0.24 
28.4±
0.35 
32.1±
1.01 
35.9±
0.9 
107.5
±1.2 
112.3
±1.36 
129.6
±1.86 
8 7.8±
0.15 
9.3±
0.91 
25.4±
0.34 
30.4±
0.65 
36.3±
0.91 
40.6±
0.82 
119.8
±1.02 
130.6
±1.57 
147.5
±1.58 
In-vitro drug release studies 
Table no. 6 shows the release of Nateglinide in 0.1N HCL at particular time, which is also represented 
graphically in figure no. 6 and 7. All the trials performed with three tablets. In all the formulations the initial 
release of the drug for the first three hours was varied between higher to lower (18 to 42%) depends on 
amount of chitosan used. The release rate was found to be controlled as the amount of chitosan increased in the 
tablet formulation. As the chitosan having property to increase the viscosity with exposed to dissolution 
medium, the release of the drug from the matrix was suppressed. The viscous and gel like structure was 
recovered at the end of dissolution study. The ‘n’ value for all the formulations varied from 0.710 – 0.890 which 
indicating that the release mechanism was non-Fickian. It can be inferred that the release was dependent on 
both relaxation of polymer and diffusion.  
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Table 6: Cumulative percentage release of Nateglinide from buoyant matrix tablets (n=3) 
Time 
In Hrs 
Percentage release of Nateglinide after each time in (hrs) ± S.D 
F1 F2 F3 F4 F5 F6 F7 F8 F9 
0 0 0 0 0 0 0 0 0 0 
1 26.63 
±1.3 
29.11 
±0.9 
22.81 
±1 
19.52 
±0.7 
22.63 
±1.3 
18.25 
±0.8 
25.53 
±0.8 
25.79 
±1.4 
23.40 
±1.2 
2 35.72
±1 
42.08 
±1.1 
33.44 
±0.8 
31.51 
±0.6 
33.82 
±0.8 
26.54 
±0.7 
34.67 
±0.7 
37.53 
±1.2 
33.37 
±1.5 
4 51.65
±0.8 
59.08 
±0.8 
50.61 
±0.9 
45.42 
±0.6 
46.41 
±1.4 
38.64 
±0.7 
48.86 
±1.8 
50.33 
±0.7 
46.24 
±0.8 
6 71.14
±1.5 
79.83 
±1 
69.25 
±1 
56.79 
±0.9 
60.68 
±1.2 
50.57 
±0.6 
65.80 
±1.4 
70.8 
±2 
59.40 
±0.7 
8 83.67
±0.9 
92.78 
±0.7 
82.45 
±0.9 
67.45 
±0.7 
76.26 
±1.1 
64.88 
±0.8 
80.05 
±1.3 
87.75 
±1.8 
70.39 
±0.7 
10 92.29
±0.7 
98.44 
±2.1 
91.73 
±0.4 
78.27 
±0.8 
92.02 
±1.1 
77.81 
±0.7 
92.10 
±0.7 
95.44 
±0.8 
82.59 
±1.5 
12 96.70
±0.7 
 95.53 
±1 
88.75 
±0.8 
98.52 
±1.7 
94.04 
±0.3 
97.27 
±1.1 
 95.50 
±0.8 
Drug release kinetics 
The in-vitro drug release data was subjected to the best fit test by linear regression analysis according 
to zero order and first order equation. Higuchi and Korsmeyer – Pappas model in order to determine the 
mechanism of the drug release. The coefficient of correlation (r) is summarized in table no. 7. The ‘r’ values of 
zero order and first order plot were compared. The ‘r’ values of zero order were in the range of 0.95 to 0.997 
where as the ‘r’ values of first order were in the range of 0.93 to 0.996. From the ‘r’ values of all the 
formulations indicating that, drug release was found to follow zero order (‘r’ value near to one). This may be 
due to poor soluble nature of Nateglinide. The drug release from the prepared buoyant tablets followed Fickian 
diffusion, since ‘n’ value of Korsmayer – Pappas plot was found in the range of 0.318 to 0.414. The ‘r’ values 
(0.98 to 0.99) from the Higuchi’s plot were inferred that the release of drug from matrix tablet was diffusion 
controlled. Hence the drug release from matrix followed zero order release and Fickian diffusion controlled. 
Table 7: Drug release kinetic studies 
Formulation Zero order First order Higuchi model Korsmeyer equation 
Regression 
coefficient (r) 
Regression 
coefficient (r) 
Regression 
coefficient (r) 
Regression 
coefficient (r) 
Exponential 
value (n) 
F1 0.962 0.962 0.987 0.992 0.318 
F2 0.953 0.933 0.981 0.983 0.331 
F3 0.962 0.962 0.990 0.992 0.363 
F4 0.984 0.984 0.988 0.994 0.340 
F5 0.997 0.992 0.983 0.995 0.364 
F6 0.996 0.996 0.966 0.995 0.414 
F7 0.989 0.989 0.995 0.994 0.367 
F8 0.970 0.963 0.982 0.990 0.344 
F9 0.992 0.987 0.983 0.996 0.338 
CONCLUSION 
From the results, we conclude that buoyant 
drug delivery system offer a practical and suitable 
approach to prepare controlled release of Nateglinide 
with chitosan as rate controlling agent to enhance 
bioavailability and dose reducing frequency. Based 
on all observations and results, it is conferred that 
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there is no incompatibility between Nateglinide and 
all other excipients used in the tablet formulations 
with required floating time and drug release. 
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Figures 
 
Fig. 1- IR spectrum of Nateglinide 
 
 
Fig. 2: IR Spectrum of Nateglinide with Excipients 
 
 
Fig. 3: Swelling Index of formulation F1 – F4 
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Fig. 4: Swelling Index of formulation F5 – F9 
 
Fig. 5: Swelling behavior 
 
Fig. 6: In-vitro drug release profile. (F1 – F4) 
 
Fig. 7: In-vitro drug release profile. (F5 – F9) 
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